AskBio Announces First Patient Randomized in Phase 1 Trial of AB-1005 Gene Therapy for Multiple System Atrophy-Parkinsonian Type
Asklepios BioPharmaceutical, Inc., a gene therapy firm fully owned and independently operated under Bayer AG, announced the initiation of the Phase I REGENERATE MSA-101 clinical trial for AB-1005 at the Ohio State University Wexner Medical Center. The first patient has been randomized in this trial, representing a noteworthy advancement in the development of AB-1005 gene therapy. AB-1005, an adeno-associated viral vector encoding glial cell line-derived neurotrophic factor (AAV2-GDNF), is targeted for the treatment of multiple system atro...
